Mission SUPPORT BASIC RESEARCH TO DEVELOP DRUGS, DIAGNOSTICS, AND VACCINES FOR EMERGING AND REEMERGING INFECTIONS AND BIODEFENSE. The Duke RBL supports.

Slides:

Advertisements

Similar presentations

Photo by gunnisal, Flickr Instituto Nacional de Saúde de Moçambique Novemer 3, 2009 An HDR CUH2A Initiative.

Advertisements

Center for Biologics Evaluation and Research

Health and Safety in the Laboratory

The Laboratory Response Network

Department of Public Health and Social Services Guam Public Health Laboratory (GPHL) March 11, 2014.

VIRAL AND ZOONOTIC DISEASE RESEARCH PROGRM VZDRP Study. Monitor. Detect Empowering nations and agencies through collaboration, with the means to better.

Overview of the Division of Viral Products

Medical Diagnostics NIAID Funding Opportunities Maria Y. Giovanni, Ph.D. Assistant Director for Microbial Genomics and Advanced Technologies National Institute.

The Laboratory Response Network

Biodefense-related Research UMDNJ-New Jersey Medical School Nancy Connell, Ph.D. Director, UMDNJ Center for Biodefense Vice-chair for Research Department.

CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

Institutional Biosafety Committee and Biological Use Authorization.

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

SARS Epidemic: A Global Challenge Bong-Min Yang, PhD & Sung-il Cho, MD, PhD of School of Public Health Seoul National University.

New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research.

THE ROLE OF OIE COLLABORATING CENTRES IN STRENGTHENING OF VETERINARY SERVICES Center for Animal Health and Food Safety :: Global Initiative for Food Systems.

Association of Public Health Laboratories National Center for Public Health Laboratory Leadership Cohort IV.

MICHIGAN DEPARTMENT OF AGRICULTURE A NIMAL INDUSTRY DIVISION JOAN M. ARNOLDI, D.V.M., M.S. State Veterinarian and Division Director NANCY A. FRANK, D.V.M.,

Emerging and Zoonotic Infectious Diseases

Freimann Life Science Center (FLSC)  State-of-the-art animal research facility  30,000 square feet, flexible use  Fully accredited and registered 

Bioterrorism MLAB 2434: Microiology Keri Brophy-Martinez.

Biosafety and the Southeast Asian Clinical Infectious Diseases Network (SEAICRN) Rogier van Doorn Clinical Microbiologist Wellcome Trust Major Overseas.

Germs Go Global Why Emerging Infectious Diseases Are a Threat to America Jeff Levi, PhD Executive Director Congressional Briefing April 17, 2009.

Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.

Biosafety Recommendations for Laboratory Testing for TB

The Global Threat of Infectious Diseases Background 20 th Century Re-Emergence of Infectious Diseases - Newly recognized diseases - Known diseases -

National Institute of Health Pathom Sawanpanyalert, MD, DrPH National Institute of Health Department of Medical Sciences Ministry of Public Health, Thailand.

SARS Research Resources at NIAID Linda C. Lambert, Ph.D. Program Officer Influenza, SARS, and Related Viral Respiratory Diseases NIAID/NIH/DHHS.

1 WHO Communicable Diseases, Surveillance & Response SARS Diagnostics and Laboratory Needs: the WHO Perspective C.E. Roth Dangerous and New Pathogens Global.

Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.

United States Army Medical Research Institute of Infectious Diseases KYLE MELLING.

Avian Influenza Tanzania Yongolo MGS, Swai E, Chuwa JKM, Malick A. Ministry of Livestock, Ministry of Health and Social Welfare Tanzania Mainland and Zanzibar.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

West Nile Virus: Pathogenesis and Diagnostic Tools Maria Rios, PhD - Senior Staff Fellow Laboratory of Molecular Virology DETTD/OBRR/CBER/FDA WNV epidemic.

Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.

Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.

Emerging and Re-emerging Infectious Diseases Samantha Rosenthal, MPH, PhD Candidate.

Regional Centers of Excellence Program in Biodefense Samuel L. Stanley, Jr., M.D. Director, Midwest Regional Center of Excellence in Biodefense and Emerging.

The Integrated National Biodefense Portfolio Initiative “One-Portfolio” Chemical Biological Defense Acquisition Initiatives Forum (CBDAIF) May 6, 2009.

Division of Hematology Emergency Preparedness Action Initiatives Prepared by Mark Weinstein, Ph.D., Dorothy Scott M.D. and Basil Golding M.D. Division.

Centers for Disease Control and Prevention (CDC): Fighting Diseases Worldwide Presented by: Angela Permon Resident Scientist Snook ISD Presented by: Angela.

Public Health Data Standards Consortium

“28,424 cases of Ebola and still counting—what have we learned

Thomas S. Bundt, PhD., FACHE COL, MS Commander, USAMRIID

OFFICE OF VACCINES RESEARCH AND REVIEW Center for Biologics Evaluation and Research Michael J. Brennan, Ph.D. Associate Director for Research OVRR Site.

Objectives  Define risk assessment as it relates to biosafety  Understand the risk assessment process and how to implement it  Discuss risk factors.

Overview Founded: 1963 in Vienna, Austria Activity: Distribution of products and services for Life Science, Research and Diagnostics Employees: 22 7 product.

Jean B. Patel, PhD, D(ABMM) Division of Healthcare Quality Promotion National Center for Emerging and Zoonotic Infectious Disease Centers for Disease Control.

Diagnostic Testing for Zika Virus Frederick S. Nolte, PhD, D(ABMM), F(AAM) Professor and Vice-Chair for Laboratory Medicine Department of Pathology and.

11/21/2014 CFAR Mentoring Core Facilities at UCSF and Beyond Teri Liegler, PhD Director ARI-UCSF Laboratory of Clinical Virology CFAR Virology Core Laboratory.

ZIKA CASES (1/15 -9/7/16) USA- 2,964 total Travel associated 2,920

Institutional Biosafety Committee (IBC)

In The Name of God.

Bioterrorism: A Changing World and What You Can Do

Office of Research Administration: Clinical Research Contracting

What we all need to know about the powers that be!

Working with Biological Hazards

UCSF Core Facilities Enterprise

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Cedric Lazarus Livestock Development Officer

The Role of NICs in Influenza Surveillance

Tracking the Outbreak of HIV using ELISA Assays

Week 15 Vocab Definitions

Public health measures toward prevention

KEY CONCEPT Some viral diseases can be prevented with vaccines.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

KEY CONCEPT Some viral diseases can be prevented with vaccines.

Samia Metwally, DVM, PhD (FAO)

Presentation transcript:

Supporting the advancement of biodefense and infectious disease research

Mission SUPPORT BASIC RESEARCH TO DEVELOP DRUGS, DIAGNOSTICS, AND VACCINES FOR EMERGING AND REEMERGING INFECTIONS AND BIODEFENSE. The Duke RBL supports sponsored research programs in the areas of: Safety and Biopreparedness Vaccine/Therapeutic Development Host Response / Immune Monitoring Proficiency Testing / Quality Assurance Excess research support capacity in the RBL is available to investigators through the collaborative shared research units.

Units The Duke RBL provides customized full or partial support to meet your animal model and laboratory study needs. Request services or an estimate through coreresearch.duke.edu, or contact us to discuss your specific needs. The Duke RBL is fully approved for BSL3 and CDC select agent research. The RBL has six fully-equipped 800 ft2 BSL2 lab suites, seven 180 ft2 BSL3 lab suites, and a 250 ft2 BSL2/3 cell sorting suite with a BD FACS Aria II. The RBL also has two animal BSL2/3 suites, each with a procedure room and two animal holding areas (mouse, rabbit, ferret). The RBL vivarium is also equipped with two aerobiology exposure systems and IVIS live animal imaging.

Leadership THE DUKE RBL IS A DIVISION OF THE DUKE HUMAN VACCINE INSTITUTE, DUKE SCHOOL OF MEDICINE Gregory D. Sempowski, PhD Director 919.684.4386 greg.sempowski@duke.edu Scott Alderman, MS Associate Director for Safety and Operations 919.668.6593 scott.alderman@duke.edu Heather E. Lynch, PhD Assistant Director for Program Management and Development 919.681.2935 heather.lynch@duke.edu

Services Andrew Macintyre, PhD Unit Manager 919.668.4704 a.n.macintyre@duke.edu Services Commercial Luminex biomarker assays Sample preparation (small animal, human, NHP) Histopathology and immunophenotyping ELISA (commercial, custom antigen specific) Molecular assays (sjTREC, PCR arrays,TCR sequencing) Core Research Code: D-0002

Services Rose Asrican, MS Unit Coordinator 919.681.5480 rosemarie.asrican@duke.edu Services Quality-controlled stock propagation Mouse challenge models for plague, TB, tularemia, Cryptococcus, and others Specializing in whole body aerosol exposure MIC screening and FCU/IFU assays Core Research Code: D-0045

Services Charles E. McGee, PhD Unit Manager 919.681.9824 charles.mcgee@duke.edu Services Quality-controlled stock propagation Viral load quantification Virus serology assays (HAI, PRNT, microneutralization) Small animal challenge models for influenza, West Nile, Zika, and others Core Research Code: D-0031

Contact Global Heath Research Building 909 S. LaSalle St., Durham, NC 27710 Phone: 919.684.3349 Email: RBLINFO@duke.edu The Duke Regional Biocontainment Laboratory (RBL) was built with funding from the NIH (UC6-AI58607)